Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus
ABSTRACT Sulfonylureas (SU) are commonly prescribed as oral hypoglycemic agents for the management of diabetes mellitus (DM). We postulated that SU possess antimicrobial properties due to their structural resemblance to the antimicrobial agent sulfamethoxazole. Using data from Taiwan's National...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/psp4.13308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725508906909696 |
|---|---|
| author | Yu‐ying Wu I‐Fan Lin Kuan‐Hua Chen Hsi‐Hao Wang Chun‐Kai Huang |
| author_facet | Yu‐ying Wu I‐Fan Lin Kuan‐Hua Chen Hsi‐Hao Wang Chun‐Kai Huang |
| author_sort | Yu‐ying Wu |
| collection | DOAJ |
| description | ABSTRACT Sulfonylureas (SU) are commonly prescribed as oral hypoglycemic agents for the management of diabetes mellitus (DM). We postulated that SU possess antimicrobial properties due to their structural resemblance to the antimicrobial agent sulfamethoxazole. Using data from Taiwan's National Health Insurance Research Database, we enrolled patients diagnosed with DM between 2000 and 2013 and followed them for a three‐year period. Patients who consistently used SU were categorized into the SU cohort, while those who had never used SU formed the non‐sulfonylurea (non‐SU) cohort. The primary study endpoints were diagnoses of pneumonia and urinary tract infections (UTIs). Within the database, we identified a total of 15,458,554 patients with DM, with 754,601 (4.88%) in the SU cohort and 2,244,436 (14.52%) in the non‐SU cohort. After individual matching based on age, gender, index day, and propensity score of comorbidities, we included 663,056 patients in each cohort. The cumulative incidence of pneumonia and UTI was 29,239 (4.41%) and 60,733 (9.16%) in the SU cohort, respectively, and 24,599 (3.71%) and 56,554 (8.53%) in the non‐SU cohort, respectively. Our findings indicated that the use of SU increased the risk of pneumonia (1.26–1.60 times) and UTI (1.13–1.22 times), while also potentially offsetting the protective effects of metformin. This pharmacoepidemiological study represents a concerted effort to assess latent drug properties that may have a significant impact on the clinical management of patients with DM. |
| format | Article |
| id | doaj-art-e581ca8a82d94204a1718e7cfcf5ee18 |
| institution | DOAJ |
| issn | 2163-8306 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | CPT: Pharmacometrics & Systems Pharmacology |
| spelling | doaj-art-e581ca8a82d94204a1718e7cfcf5ee182025-08-20T03:10:27ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062025-04-0114471872510.1002/psp4.13308Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes MellitusYu‐ying Wu0I‐Fan Lin1Kuan‐Hua Chen2Hsi‐Hao Wang3Chun‐Kai Huang4Graduate Institute of Adult Education National Kaohsiung Normal University Kaohsiung TaiwanSchool of Medicine, College of Medicine I‐Shou University Kaohsiung TaiwanSchool of Medicine, College of Medicine I‐Shou University Kaohsiung TaiwanSchool of Medicine, College of Medicine I‐Shou University Kaohsiung TaiwanSchool of Medicine, College of Medicine I‐Shou University Kaohsiung TaiwanABSTRACT Sulfonylureas (SU) are commonly prescribed as oral hypoglycemic agents for the management of diabetes mellitus (DM). We postulated that SU possess antimicrobial properties due to their structural resemblance to the antimicrobial agent sulfamethoxazole. Using data from Taiwan's National Health Insurance Research Database, we enrolled patients diagnosed with DM between 2000 and 2013 and followed them for a three‐year period. Patients who consistently used SU were categorized into the SU cohort, while those who had never used SU formed the non‐sulfonylurea (non‐SU) cohort. The primary study endpoints were diagnoses of pneumonia and urinary tract infections (UTIs). Within the database, we identified a total of 15,458,554 patients with DM, with 754,601 (4.88%) in the SU cohort and 2,244,436 (14.52%) in the non‐SU cohort. After individual matching based on age, gender, index day, and propensity score of comorbidities, we included 663,056 patients in each cohort. The cumulative incidence of pneumonia and UTI was 29,239 (4.41%) and 60,733 (9.16%) in the SU cohort, respectively, and 24,599 (3.71%) and 56,554 (8.53%) in the non‐SU cohort, respectively. Our findings indicated that the use of SU increased the risk of pneumonia (1.26–1.60 times) and UTI (1.13–1.22 times), while also potentially offsetting the protective effects of metformin. This pharmacoepidemiological study represents a concerted effort to assess latent drug properties that may have a significant impact on the clinical management of patients with DM.https://doi.org/10.1002/psp4.13308antidiabetic sulfonamidesinfectionpharmacoepidemiologypopulation‐based studysulfonylurea |
| spellingShingle | Yu‐ying Wu I‐Fan Lin Kuan‐Hua Chen Hsi‐Hao Wang Chun‐Kai Huang Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus CPT: Pharmacometrics & Systems Pharmacology antidiabetic sulfonamides infection pharmacoepidemiology population‐based study sulfonylurea |
| title | Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus |
| title_full | Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus |
| title_fullStr | Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus |
| title_full_unstemmed | Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus |
| title_short | Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus |
| title_sort | using pharmacoepidemiology to examine the interplay of sulfonylureas and infection risk in patients with diabetes mellitus |
| topic | antidiabetic sulfonamides infection pharmacoepidemiology population‐based study sulfonylurea |
| url | https://doi.org/10.1002/psp4.13308 |
| work_keys_str_mv | AT yuyingwu usingpharmacoepidemiologytoexaminetheinterplayofsulfonylureasandinfectionriskinpatientswithdiabetesmellitus AT ifanlin usingpharmacoepidemiologytoexaminetheinterplayofsulfonylureasandinfectionriskinpatientswithdiabetesmellitus AT kuanhuachen usingpharmacoepidemiologytoexaminetheinterplayofsulfonylureasandinfectionriskinpatientswithdiabetesmellitus AT hsihaowang usingpharmacoepidemiologytoexaminetheinterplayofsulfonylureasandinfectionriskinpatientswithdiabetesmellitus AT chunkaihuang usingpharmacoepidemiologytoexaminetheinterplayofsulfonylureasandinfectionriskinpatientswithdiabetesmellitus |